SecBot SecBot

ARVN

ARVINAS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001655759 Biotech & Drug Discovery
$6.77 −0.05 (−0.73%)
Nov 16 4:00 PM ET · prev $6.82
Market cap
$446.6M
Small cap
Consensus
Buy
57% Buy or better · 23 analysts
Median target
$13.00
+92% · range $8.00–21.00
1 year
−38.7%
from $11.04 · Nov 17
30 days
−6.7%
from $7.26
52-week range
$6.41–13.83
−51% from high · low Nov 6
Avg volume 20D
955.9K
shares / day
Short interest
5.75M
≈8.8% of shares · +2.8%
Days to cover
7.6
at average volume
Insider net
−$904.6K
1 buyer · 6 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $268.1K at an average $13.40. 6 insiders sold $1.2M. Price is 49% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 21 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    13 of 23 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.849 → −$0.767 over 90 days. 9 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +2.8% to 5.75M shares. 7.6 days to cover, ≈8.8% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdTRIM1,135,672$8.8M
UBS Group AGADD600,728$4.6M
RENAISSANCE TECHNOLOGIES LLCDOUBLED577,616$4.5M
FMR LLCADD515,238$4.0M
HRT FINANCIAL LPDOUBLED399,550$3.1M
Connor, Clark & Lunn Investment Management Ltd.ADD305,336$2.4M
LOS ANGELES CAPITAL MANAGEMENT LLCADD127,642$987.3K
BARCLAYS PLCADD109,674$848.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 57% rate it Buy or better
Strong Buy4Buy9Hold9Sell1Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +92%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 3, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 10, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Aug 10, 2026Citigroup
MAINTAIN
MAINTAINBuy
Aug 5, 2026Wells Fargo
DOWNGRADE
DOWNGRADEEqual-Weight
Aug 5, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Aug 4, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$268.1K
bought · 1 insider
$1.2M
sold · 6 insiders
−49.5%
vs their $13.40 cost
DateInsiderTypeValue
Nov 9, 2026
Loomis David K
VP, Chief Accounting Officer
Nov 9, 2026
SELL$1.5K
Jun 24, 2026
Saik Andrew
Chief Financial Officer
Jun 24, 2026
SELL$46.5K
Jun 24, 2026
Bain Linda
Director
Jun 24, 2026
AWARD15,527 sh
Jun 24, 2026
Bain Linda
Director
Jun 24, 2026
AWARD22,714 sh
Jun 24, 2026
Norwalk Leslie V
Director
Jun 24, 2026
AWARD15,527 sh
Jun 24, 2026
Norwalk Leslie V
Director
Jun 24, 2026
AWARD22,714 sh
Jun 24, 2026
Morrison Briggs
Director
Jun 24, 2026
AWARD15,527 sh
Jun 24, 2026
Morrison Briggs
Director
Jun 24, 2026
AWARD22,714 sh

Earnings setup

Estimates
−$0.77
EPS estimate, this quarter
+10%
estimate change, 90 days
9↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.77-$0.98–-$0.44+17.3%$11.9M
Next Q-$0.79-$0.95–-$0.55+12.1%$12.6M
Current FY🔒 Fresh data, subscribers only
Next FY-$3.18-$4.26–-$2.01+1.7%$47.8M

Short side

FINRA· Oct 30, 2026
5,751,346
shares short
+2.8%
vs prior settlement
7.6
days to cover
≈8.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Other
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage b
Nov 9, 2026 Insider
Loomis David K sold 232 shares
VP, Chief Accounting Officer @ $6.36 ($1.5K)
Nov 3, 2026 SEC
Arvinas filed a universal shelf registration statement to offer up to $400M in securities, including a $200M ATM…
S-3 · Impact 5/10
Nov 3, 2026 SEC
Arvinas reported Q3 2026 revenue of $0.5M, down 98.8% from $41.9M a year ago, as Pfizer collaboration revenue ended…
8-K · Impact 5/10
Nov 3, 2026 SEC
Arvinas reported Q3 2026 revenue of $0.5M, down from $41.9M a year ago, as Pfizer collaboration revenue did not recur…
PRESS-RELEASE · Impact 4/10
Sep 30, 2026 Inst.
Qube Research & Technologies · TRIM
1,135,672 shares ($8.8M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
600,728 shares ($4.6M)
Jun 24, 2026 Insider
Saik Andrew sold 5,696 shares
Chief Financial Officer @ $8.16 ($46.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent
Nov 11, 2026
Press release
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of…
Nov 3, 2026
Earnings
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation
Nov 3, 2026
Earnings result
ARVN Q3 2026 Earnings: EPS $-0.82 (+7.7% vs est)
Oct 27, 2026
Press release
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
$25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation
Oct 27, 2026
Earnings
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of…

SecBot reports

18 filings · 3 press releases · 3 bullish · 5 bearish · 1 mixed · 9 neutral
All ARVN filing & press-release reports (21)